Acute myeloblastic leukemia with maturation

Worldwide Chronic Myeloid Leukemia (CML) Treatment Industry to 2029 - Future in Non-invasive and Efficient Treatment Options Presents Opportunities

Retrieved on: 
Wednesday, March 31, 2021
Chronic myeloid leukemia, Acute myeloid leukemia, Chronic myelogenous leukemia, Leukemia, Myeloid tissue, Acute myeloblastic leukemia with maturation, Philadelphia chromosome

The report provides detailed intelligence about the chronic myeloid leukemia (CML) treatment market.

Key Points: 
  • The report provides detailed intelligence about the chronic myeloid leukemia (CML) treatment market.
  • The report includes detailed analysis on market dynamics, market estimation and forecast for the period of 2019 to 2029.
  • The report also covers the impact of covid 19 on the growth and revenues of the CML treatment market.
  • Chronic Myeloid Leukemia affects the white blood cells known as myeloid cells.

2020 Market Study on the European Chronic Myeloid Leukemia Market and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 25, 2020
Health, Oncology, Clinical trials, Chronic myeloid leukemia, Cancer, Chemical compounds, Organic compounds, Leukemia, Chronic myelogenous leukemia, Myeloid leukemia, Morpholines, Acute myeloid leukemia, Piperazines, Acute myeloblastic leukemia with maturation, Entospletinib

The "Europe Chronic Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Chronic Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The research report Europe Chronic Myeloid Leukemia Market and Competitive Landscape - 2020, provides comprehensive insights into the Chronic Myeloid Leukemia pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Chronic Myeloid Leukemia treatment options, Chronic Myeloid Leukemia late stage clinical trials pipeline, Chronic Myeloid Leukemia prevalence by countries, Chronic Myeloid Leukemia market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Chronic Myeloid Leukemia pipeline: Find out drugs in clinical trials for the treatment of Chronic Myeloid Leukemia by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Chronic Myeloid Leukemia drugs: Identify key drugs marketed and prescribed for Chronic Myeloid Leukemia in the US, including trade name, molecule name, and company
    Chronic Myeloid Leukemia drugs sales: Find out the sales value for Chronic Myeloid Leukemia drugs by countries
    Chronic Myeloid Leukemia market valuations: Find out the market size for Chronic Myeloid Leukemia drugs in 2019 by countries.

2020 Market Study on the Acute Myeloid Leukemia Market in Europe - ResearchAndMarkets.com

Retrieved on: 
Friday, November 20, 2020
Health, Oncology, Cancer, Chemical compounds, Leukemia, Clinical medicine, Acute myeloid leukemia, Myeloid leukemia, Morpholines, Antibody-drug conjugates, Monoclonal antibodies, Acute myeloblastic leukemia with maturation, Gedatolisib

The "Europe Acute Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Acute Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Acute Myeloid Leukemia pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Acute Myeloid Leukemia treatment options, Acute Myeloid Leukemia late stage clinical trials pipeline, Acute Myeloid Leukemia prevalence by countries, Acute Myeloid Leukemia market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Acute Myeloid Leukemia pipeline: Find out drugs in clinical trials for the treatment of Acute Myeloid Leukemia by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Acute Myeloid Leukemia drugs: Identify key drugs marketed and prescribed for Acute Myeloid Leukemia in the US, including trade name, molecule name, and company
    Acute Myeloid Leukemia drugs sales: Find out the sales value for Acute Myeloid Leukemia drugs by countries
    Acute Myeloid Leukemia market valuations: Find out the market size for Acute Myeloid Leukemia drugs in 2019 by countries.

Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia

Retrieved on: 
Wednesday, September 16, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, RTT, Acute myeloid leukemia, Monocytic leukemia, Chronic myelomonocytic leukemia, Leukemia, CMML, Myeloid leukemia, 7+3, Acute myeloblastic leukemia with maturation, Acute eosinophilic leukemia

The Phase I dose escalation and expansion trial will evaluate IO-202 in patients with acute myeloid leukemia (AML) with monocytic differentiation and in chronic myelomonocytic leukemia (CMML).

Key Points: 
  • The Phase I dose escalation and expansion trial will evaluate IO-202 in patients with acute myeloid leukemia (AML) with monocytic differentiation and in chronic myelomonocytic leukemia (CMML).
  • In preclinical studies, IO-202 has shown evidence of activating T cell cytotoxicity against leukemia cells and blocking leukemia infiltration.
  • The dose-escalation phase of the trial will identify the optimal dose of IO-202.
  • Despite advances in treatment, less than 30 percent of acute myeloid leukemia patients are alive five years after initial diagnosis.

2020 Insights on Acute Myeloid Leukemia - Global Market and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 8, 2020
Health, Other Health, Cancer, RTT, Chemical compounds, Clinical medicine, Leukemia, Acute myeloid leukemia, Myeloid leukemia, Acute myeloblastic leukemia with maturation, Gedatolisib

The "Global Acute Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acute Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Acute Myeloid Leukemia pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Acute Myeloid Leukemia treatment options, Acute Myeloid Leukemia late stage clinical trials pipeline, Acute Myeloid Leukemia prevalence by countries, Acute Myeloid Leukemia market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Acute Myeloid Leukemia pipeline: Find out drugs in clinical trials for the treatment of Acute Myeloid Leukemia by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Acute Myeloid Leukemia drugs: Identify key drugs marketed and prescribed for Acute Myeloid Leukemia in the US, including trade name, molecule name, and company
    Acute Myeloid Leukemia drugs sales: Find out the sales value for Acute Myeloid Leukemia drugs by countries
    Acute Myeloid Leukemia market valuations: Find out the market size for Acute Myeloid Leukemia drugs in 2019 by countries.

Global Chronic Myeloid Leukemia Industry Study 2020 - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Retrieved on: 
Friday, June 26, 2020
Pharmaceutical, Health, Oncology, Chronic myeloid leukemia, Cancer, RTT, Leukemia, Acute myeloid leukemia, Chemical compounds, Chronic myelogenous leukemia, Myeloid leukemia, Morpholines, Clinical medicine, Acute myeloblastic leukemia with maturation, Entospletinib

The "Global Chronic Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chronic Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Chronic Myeloid Leukemia pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Chronic Myeloid Leukemia treatment options, Chronic Myeloid Leukemia late stage clinical trials pipeline, Chronic Myeloid Leukemia prevalence by countries, Chronic Myeloid Leukemia market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Chronic Myeloid Leukemia pipeline: Find out drugs in clinical trials for the treatment of Chronic Myeloid Leukemia by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Chronic Myeloid Leukemia drugs: Identify key drugs marketed and prescribed for Chronic Myeloid Leukemia in the US, including trade name, molecule name, and company
    Chronic Myeloid Leukemia drugs sales: Find out the sales value for Chronic Myeloid Leukemia drugs by countries
    Chronic Myeloid Leukemia market valuations: Find out the market size for Chronic Myeloid Leukemia drugs in 2019 by countries.

Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance

Retrieved on: 
Friday, May 29, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, RTT, Leukemia, Myeloid leukemia, Acute myeloid leukemia, Myeloid sarcoma, Acute myeloblastic leukemia with maturation

Acute myeloid leukemia is a devastating disease that needs new approaches and better treatment options.

Key Points: 
  • Acute myeloid leukemia is a devastating disease that needs new approaches and better treatment options.
  • We look forward to working with investigators as we advance the first anti-LILRB4 antibody into the clinic.
  • Despite advances in treatment, less than 30 percent of acute myeloid leukemia patients are alive five years after initial diagnosis.
  • Immune-Oncs lead program IO-202, a first-in-class antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers.

The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13%

Retrieved on: 
Monday, January 13, 2020
RTT, Cancer, Leukemia, Acute myeloid leukemia, Myeloid tissue, Myeloid leukemia, Tyrosine kinase inhibitors, Acute myeloblastic leukemia with maturation, Acute leukemia

- This report discusses Porters Five Forces analysis of the acute myeloid leukaemia market.

Key Points: 
  • - This report discusses Porters Five Forces analysis of the acute myeloid leukaemia market.
  • - This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.
  • - What are the drivers and restraints for the growth of the acute myeloid leukemia market?
  • - What are the market shares of each segment of the overall acute myeloid leukemia market in 2019?

Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients

Retrieved on: 
Friday, January 10, 2020
Medical specialties, Medicine, Acute myeloid leukemia, Clinical medicine, RTT, Hematology, Stem cells, Transplantation medicine, Hematopoietic stem cell transplantation, Leukemia, Haematopoiesis, Acute myeloblastic leukemia with maturation

Acute myeloid leukemia (AML) is a malignant disease of the hematopoietic system, affecting mainly adults above 60 years of age.

Key Points: 
  • Acute myeloid leukemia (AML) is a malignant disease of the hematopoietic system, affecting mainly adults above 60 years of age.
  • AML is a heterogeneous type of cancer affecting patients blood and bone marrow.
  • However, HSCT induces high morbidity and mortality and only less than half of the AML patients can be treated with HSCT.
  • A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.

Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia

Retrieved on: 
Wednesday, December 4, 2019
RTT, Acute myeloid leukemia, Leukemia, Myeloid leukemia, Clinical medicine, Acute myeloblastic leukemia with maturation

A report from Mordor Intelligence states: "The global acute myeloid leukemia market was valued atUSD 701.6 millionin 2018, and is estimated to be valued atUSD $1,539.99 millionin 2024, witnessing a CAGR of 14.0%.

Key Points: 
  • A report from Mordor Intelligence states: "The global acute myeloid leukemia market was valued atUSD 701.6 millionin 2018, and is estimated to be valued atUSD $1,539.99 millionin 2024, witnessing a CAGR of 14.0%.
  • The American Cancer Society's estimates for leukemia inthe United States, for 2019, indicates that approximately 61,780 new cases of leukemiaand 22,840 deaths from leukemia are expected to occur in the country.
  • Among them, the number of new cases of acute myeloid leukemia (AML) will be around21,450, from which most of the population will be adults.
  • This statistic shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impactthe growth of the AML market inthe United States.